$DECN COVID-19 CORONAVIRUS TESTING DEVICE $$$$$$
short interest up 100% thus squeese is in effect :)
Share Structure
Market Cap Market Cap
3,039,984
03/02/2020
Authorized Shares
494,995,000
02/07/2020
Outstanding Shares
159,999,161
02/07/2020
Restricted
6,611,501
02/07/2020
Unrestricted
153,387,660
02/07/2020
DECN Jumps into Screening and Testing Channel For Coronavirus (COVID19) Using Its Innovative Impedance Technology First Implemented In Its GenUltimate TBG
Press Release | 03/03/2020
new genvirotm technology anticipated to be commercial ready in summer 2020, government fast track and waivers begun, cost per screen expected to be $4.95, unique reporting method to be used
LOS ANGELES, CA / ACCESSWIRE / March 3, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) is an 18-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, its GenAccord! systems for the uninsured and under-insured, its GenChoice! ("Ladybug") test strip now in the later stages of FDA 510(k) prosecution, and its GenUltimate Precis products manufactured for International markets.
Today, in a break-through discussed for the first time, DECN announces in this first of three releases, expected in the next 10 days, the introduction of our new screening methodology for the Coronavirus (Covid19). Our product is timely, simple to use, cost effective and will be commercial ready in the summer of 2020.
Keith Berman, CEO of DECN commented, "We have the technology perfected which will take months off of the development schedule. Our impedance powered diagnostic will be field tested at ground-zero in Daegu, Korea, where 700+ people have already been overcome by Coronavirus (COVID19) and where all of the clinical studies for our "Gen" products were tested. Our timing here is spot-on."
News 
Market Data 
Discover 
